Secukinumab provides sustained low rates of radiographic progression in psoriatic arthritis: 52-week results from a phase 3 study, FUTURE 5
暂无分享,去创建一个
D. M. van der Heijde | R. Landewé | P. Rahman | P. Mease | S. Navarra | Xuan Zhu | A. Singhal | H. Tahir | L. Pricop | G. Ligozio | S. Mpofu | E. Boettcher | A. Readie